Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Industry, Sector and Symbol
Industry Metal mining
Sub-IndustryN/A
SectorMedical
Phone310-598-5410
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.45 million
Profitability
Miscellaneous
Employees11
Next Earnings DateN/A
OptionableNot Optionable
Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions
What is Opiant Pharmaceuticals' stock symbol?
Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How were Opiant Pharmaceuticals' earnings last quarter?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings results on Thursday, August, 9th. The technology company reported ($0.52) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.07) by $0.55. The technology company earned $3.15 million during the quarter, compared to analysts' expectations of $2.10 million. Opiant Pharmaceuticals had a negative net margin of 187.13% and a negative return on equity of 175.03%. View Opiant Pharmaceuticals' Earnings History.
What price target have analysts set for OPNT?
1 brokers have issued 12-month target prices for Opiant Pharmaceuticals' stock. Their predictions range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 186.7% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.
What is the consensus analysts' recommendation for Opiant Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.
Has Opiant Pharmaceuticals been receiving favorable news coverage?
Media coverage about OPNT stock has trended somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the technology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of Opiant Pharmaceuticals' key competitors?
Some companies that are related to Opiant Pharmaceuticals include Mountain Province Diamonds (MPVD), Fission Uranium (FCUUF), Amerigo Resources (ARREF), Rubicon Minerals (RBYCF), Jaguar Mining (JAGGF), Alderon Iron Ore (AXXDF), Atlatsa Resources (ATLRF), Wealth Minerals (WMLLF), Santa Fe Gold (SFEG), Silver Bull Resources (SVBL), US Gold (USAU), Quaterra Resources (QTRRF), Pacific Booker Minerals (PBMLF), VEDA RESO/PAR VTG FPD 0.1 (VDNRF) and Avalon Advanced Materials (AVLNF).
What other stocks do shareholders of Opiant Pharmaceuticals own?
Who are Opiant Pharmaceuticals' key executives?
Opiant Pharmaceuticals' management team includes the folowing people:
- Dr. Roger Crystal, CEO & Director (Age 43)
- Mr. David D. O'Toole, Chief Financial Officer (Age 60)
- Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
- Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
- Mr. Quan Vu, VP of Corp. Devel.
Who are Opiant Pharmaceuticals' major shareholders?
Opiant Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (9.33%), Essex Investment Management Co. LLC (1.30%), Northern Trust Corp (1.09%), UBS Oconnor LLC (0.64%), UBS Oconnor LLC (0.64%) and Brasada Capital Management LP (0.53%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Geoffrey Wolf, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.
Which institutional investors are selling Opiant Pharmaceuticals stock?
OPNT stock was sold by a variety of institutional investors in the last quarter, including UBS Oconnor LLC and UBS Oconnor LLC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Phil Skolnick, Roger Crystal and Thomas T Thomas. View Insider Buying and Selling for Opiant Pharmaceuticals.
Which institutional investors are buying Opiant Pharmaceuticals stock?
OPNT stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Eversept Partners LP, Brasada Capital Management LP, BlackRock Inc., Advisor Group Inc. and Northern Trust Corp. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall and David D O'toole. View Insider Buying and Selling for Opiant Pharmaceuticals.
How do I buy shares of Opiant Pharmaceuticals?
Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opiant Pharmaceuticals' stock price today?
One share of OPNT stock can currently be purchased for approximately $14.65.
How big of a company is Opiant Pharmaceuticals?
Opiant Pharmaceuticals has a market capitalization of $56.18 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.
What is Opiant Pharmaceuticals' official website?
How can I contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]
MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
